![](/img/cover-not-exists.png)
A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada
Pollock, Richard F, Norrbacka, Kirsi, Cameron, Chris, Mancillas-Adame, Leonardo, Jeddi, MarkLanguage:
english
Journal:
Journal of Comparative Effectiveness Research
DOI:
10.2217/cer-2018-0073
Date:
January, 2019
File:
PDF, 1.02 MB
english, 2019